Similar phase III results reported for dovitinib vs. sorafenib treatment in patients with metastatic renal cell carcinoma

Superior efficacy was not demonstrated by dovitinib in a head to head comparison with sorefinib in patients with metastatic renal cell carcinoma who had progressed following therapies targeting the VEGF and mTOR pathways. However, this large, phase III trial did establish a role of tyrosine kinase inhibitors in that setting. Dovitinib showed similar activity to sorafenib and generally a well tolerated safety profile. It may offer an additional treatment alternative in this group of with limited treatment options. Findings were presented during the Genitourinary Malignancies Proffered Papers Session (Abstract E17-7035) at the European Cancer Congress. Read more here.